Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Pipeline overview and financials

• Two lead assets: CRB-701 (Nectin-4 ADC for solid tumors) and CRB-913 (peripherally restricted CB1 inverse agonist for obesity).

• CRB-701 is in Phase 2/3 for cervical cancer and Phase 2 for metastatic urothelial carcinoma; FDA Fast Track granted for HNSCC and cervical cancer.

• CRB-913 is advancing in obesity, with a 16-week dose-range study (n=240) expected summer 2026.

• Cash and equivalents of $138M as of March 31, 2026; ~17.7M shares outstanding (~21.4M fully diluted).

CRB-701 clinical data and market opportunity

• In 2L+ OPSCC, CRB-701 at 3.6 mg/kg Q3W showed a 42.9% confirmed objective response rate (CORR) and 85.7% disease control rate (DCR).

• Median duration of response (DoR) was 6.3 months and progression-free survival (PFS) was 5.6 months in OPSCC.

• Safety profile highlighted low rates of peripheral neuropathy (7.3%, all grade 1/2), manageable ocular toxicity, and few discontinuations.

• OPSCC incidence is rising in the US, with HPV+ cases now 57% of HNSCC; annual incidence ~23,000 and deaths ~7,000.

• Registrational study in 2L OPSCC to launch summer 2026, targeting accelerated approval on ORR and full approval on OS.

CRB-701 in cervical cancer

• Cervical cancer market: 14,000 new US cases/year, 4,000 deaths, $1.8B market size; unmet need in 2L setting.

• CRB-701 at 3.6 mg/kg Q3W in 2L cervical cancer showed 34.4% CORR, 75% DCR, 8.0 months DoR, and 4.3 months PFS.

• Tivdak® (tisotumab vedotin) is current 2L standard with 17.8% ORR and 4.2 months PFS; CRB-701 shows potential for improved efficacy.

• FDA-aligned registrational study in 2L cervical cancer to use physician's choice (Tivdak® or chemo) as control.